Basel, Switzerland, – Lonza today announced it has received all regulatory approvals for its proposed acquisition of Capsugel S.A., further establishing its position as a leading supplier to the pharmaceutical, biotech and specialty ingredients markets.
Among its integrated solutions, Lonza offers products and services from the custom development and manufacture of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutridition indsutires.
The company provides agricultural products, advanced coatings and composites and microbial control solutions that combat viruses, bacteria and other pathogens. It also supplies drinking water sanitizers, nutraceuticals, dandruff agents and other personal care ingredients.
Founded in 1897 in the Swiss Alps, Lonza has more than 40 major manufacturing and R&D facilities and about 10,000 full-time employees worldwide.
The deal is expected to close within days.
Published on WholeFoods Online June 27, 2017